EA201400447A1 - АНТИТЕЛА К CD1d - Google Patents
АНТИТЕЛА К CD1dInfo
- Publication number
- EA201400447A1 EA201400447A1 EA201400447A EA201400447A EA201400447A1 EA 201400447 A1 EA201400447 A1 EA 201400447A1 EA 201400447 A EA201400447 A EA 201400447A EA 201400447 A EA201400447 A EA 201400447A EA 201400447 A1 EA201400447 A1 EA 201400447A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- antibodies
- cd1d
- antigen binding
- binding parts
- invention describes
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Abstract
Данное изобретение описывает изолированные антитела или их антигенсвязывающие части, связывающие CD1d. Эти антитела и их антигенсвязывающие части применяются для лечения состояний, включающих эффекторную функцию клеток NKT.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161547307P | 2011-10-14 | 2011-10-14 | |
AU2011904190A AU2011904190A0 (en) | 2011-10-14 | Antibodies to CD1d | |
PCT/AU2012/001247 WO2013053021A1 (en) | 2011-10-14 | 2012-10-15 | ANTIBODIES TO CD1d |
Publications (1)
Publication Number | Publication Date |
---|---|
EA201400447A1 true EA201400447A1 (ru) | 2014-09-30 |
Family
ID=48081279
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201400447A EA201400447A1 (ru) | 2011-10-14 | 2012-10-15 | АНТИТЕЛА К CD1d |
Country Status (14)
Country | Link |
---|---|
US (1) | US20140286957A1 (ru) |
EP (1) | EP2766042A4 (ru) |
JP (1) | JP2015502915A (ru) |
KR (1) | KR20140108520A (ru) |
CN (1) | CN104144700B (ru) |
AU (1) | AU2012323781B8 (ru) |
BR (1) | BR112014008691A2 (ru) |
CA (1) | CA2850961A1 (ru) |
EA (1) | EA201400447A1 (ru) |
IL (1) | IL231975A0 (ru) |
MX (1) | MX2014004326A (ru) |
SG (1) | SG11201400521PA (ru) |
WO (1) | WO2013053021A1 (ru) |
ZA (1) | ZA201401776B (ru) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA201791691A1 (ru) * | 2015-01-27 | 2018-01-31 | Лава Терапьютикс Б.В. | ОДНОДОМЕННЫЕ АНТИТЕЛА, НАПРАВЛЕННЫЕ НА CD1d |
KR20190065189A (ko) * | 2016-04-08 | 2019-06-11 | 어댑티뮨 리미티드 | T 세포 수용체 |
AU2017246693B2 (en) | 2016-04-08 | 2022-07-21 | Immunocore Limited | T cell receptors |
MX2018012269A (es) * | 2016-04-08 | 2019-05-30 | Adaptimmune Ltd | Receptores de celulas t. |
CN108079292A (zh) * | 2016-11-23 | 2018-05-29 | 苏州盛迪亚生物医药有限公司 | 一种抗pd-1抗体在制备治疗肝癌的药物中的用途 |
CA3056406A1 (en) * | 2017-03-15 | 2018-09-20 | Orca Biosystems Inc. | Compositions and methods for hematopoietic stem cell transplants |
MX2021003234A (es) * | 2018-09-19 | 2021-07-16 | Lava Therapeutics N V | Inmunoglobulina de la molecula cd1d de acción dual. |
GB201820006D0 (en) * | 2018-12-07 | 2019-01-23 | Lifearc | Humanised anti-IL17BR antibody |
US20240050569A1 (en) * | 2020-12-18 | 2024-02-15 | Bioardis, Llc | Mesothelin binding molecules and uses thereof |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1095062B1 (en) * | 1998-07-09 | 2006-09-13 | Brian J. Nickoloff | Method of treating disorders by modulating the interaction of natural killer receptors on t cells with their respective ligands |
AU2003234443A1 (en) * | 2002-05-01 | 2003-11-17 | Beth Israel Deaconess Medical Center | Use of anti-cd1 antibodies for the modulation of immune responses |
WO2008100912A1 (en) * | 2007-02-12 | 2008-08-21 | The General Hospital Corporation | Methods for attenuating allergen-induced airway hyperreactivity using cd1d dependent antagonists |
US8012484B2 (en) * | 2007-04-12 | 2011-09-06 | University Of Virginia Patent Foundation | Method of treating ischemia reperfusion injury by inhibiting NKT cell activity |
-
2012
- 2012-10-15 JP JP2014534890A patent/JP2015502915A/ja active Pending
- 2012-10-15 EP EP12840164.3A patent/EP2766042A4/en not_active Withdrawn
- 2012-10-15 WO PCT/AU2012/001247 patent/WO2013053021A1/en active Application Filing
- 2012-10-15 EA EA201400447A patent/EA201400447A1/ru unknown
- 2012-10-15 AU AU2012323781A patent/AU2012323781B8/en not_active Ceased
- 2012-10-15 MX MX2014004326A patent/MX2014004326A/es unknown
- 2012-10-15 BR BR112014008691A patent/BR112014008691A2/pt unknown
- 2012-10-15 KR KR1020147012848A patent/KR20140108520A/ko not_active Application Discontinuation
- 2012-10-15 CA CA2850961A patent/CA2850961A1/en not_active Abandoned
- 2012-10-15 CN CN201280050432.2A patent/CN104144700B/zh not_active Expired - Fee Related
- 2012-10-15 SG SG11201400521PA patent/SG11201400521PA/en unknown
-
2014
- 2014-03-11 ZA ZA2014/01776A patent/ZA201401776B/en unknown
- 2014-04-07 IL IL231975A patent/IL231975A0/en unknown
- 2014-04-10 US US14/249,566 patent/US20140286957A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
BR112014008691A2 (pt) | 2017-06-13 |
CN104144700B (zh) | 2016-10-19 |
NZ622050A (en) | 2016-07-29 |
AU2012323781B8 (en) | 2015-05-14 |
SG11201400521PA (en) | 2014-08-28 |
MX2014004326A (es) | 2014-09-25 |
US20140286957A1 (en) | 2014-09-25 |
ZA201401776B (en) | 2016-01-27 |
AU2012323781B2 (en) | 2015-04-23 |
KR20140108520A (ko) | 2014-09-11 |
IL231975A0 (en) | 2014-05-28 |
EP2766042A1 (en) | 2014-08-20 |
AU2012323781A1 (en) | 2014-03-27 |
AU2012323781A8 (en) | 2015-05-14 |
JP2015502915A (ja) | 2015-01-29 |
CN104144700A (zh) | 2014-11-12 |
WO2013053021A1 (en) | 2013-04-18 |
EP2766042A4 (en) | 2015-05-27 |
CA2850961A1 (en) | 2013-04-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1122278T1 (el) | Αντι il-36r αντισωματα | |
CY1120181T1 (el) | Αντι-cd40 αντισωματα | |
EA201890285A1 (ru) | Антитела против pd-1, активируемые антитела против pd-1 и способы их применения | |
EA201400447A1 (ru) | АНТИТЕЛА К CD1d | |
EA201400875A1 (ru) | Антитела к cd47 и способы их применения | |
CY1121742T1 (el) | Αντισωματα s100a4 και θεραπευτικες χρησεις αυτων | |
EA201390929A1 (ru) | Антитела к pcsk9 и способы их применения | |
EA201201016A1 (ru) | Антидоты антикоагулянтов | |
EA201490778A1 (ru) | АНТИТЕЛА ПРОТИВ HtrA1 И СПОСОБЫ ПРИМЕНЕНИЯ | |
EA201491947A1 (ru) | Антитела и иммуноконъюгаты к ly6e и способы применения | |
EA201791693A1 (ru) | Гетеродимерные иммуноглобулины | |
EA201491224A1 (ru) | Анти-псф-тау-антитела и их применение | |
EA201401077A1 (ru) | Биспецифические антитела к человеческому tweak и человеческому il17 и их применения | |
EA201590993A1 (ru) | Гетеродимерные иммуноглобулины | |
EA201491811A1 (ru) | АНТИ-LgR5 АНТИТЕЛА И ИММУНОКОНЪЮГАТЫ | |
CL2017002283A1 (es) | Formulaciones de anticuerpos y métodos (divisional de solicitud n°1081-2014) | |
EA201500995A1 (ru) | Биспецифические антитела, специфические в отношении fap и dr5, антитела, специфические в отношении dr5, и способы их применения | |
EA201590247A1 (ru) | Антитела к siglec-15 | |
EA201491541A1 (ru) | АНТИТЕЛА ПРОТИВ ИНТЕГРИНОВ αvβ6 И ИХ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ ЗЛОКАЧЕСТВЕННЫХ НОВООБРАЗОВАНИЙ | |
EA201491357A1 (ru) | Анти-lrp5 антитела и способы их применения | |
EA201591974A1 (ru) | Антитела человека, связывающиеся с g-белком rsv | |
CL2014001640A1 (es) | Composiciones y metodos para anticuerpos dirigidos factor de p; y usos del anticuerpo. | |
EA201391389A1 (ru) | Кристаллы антител против склеростина и составы на их основе | |
EA201391248A1 (ru) | Биспецифические связывающие агенты | |
EA201291065A1 (ru) | Антитела против vla-4 |